CTI Clinical Trial and Consulting Services Announces Polish Office and Subsidiary
[Cincinnati, OH ~ May 13, 2013] CTI Clinical Trial and Consulting Services (CTI) announces that it has opened an office in Warsaw, Poland. The office is opened through its newly created wholly-owned subsidiary, CTI Clinical Trial and Consulting Services Poland, sp. z o.o.
“Poland, the sixth largest country in Europe, has both a highly educated population and one of the fastest growing economies in the EU right now,” states Patrick Earley, General Manager at CTI. “Having an office there is an excellent opportunity for CTI to collaborate with leading universities, medical centers, and thought leaders, in addition to the pharmaceutical and biotechnology companies throughout the country. We are very happy to continue our growth and expansion across Europe.”
CTI has been working for nearly fifteen years in the drug development industry in North America, Europe, and South America, specializing in clinical research programs involving critically ill patient populations.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and delivers high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III POETYK PsA Trials Show Significant Clinical Benefit with Sotyktu in Psoriatic Arthritis
June 13th 2025New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in adults with active psoriatic arthritis, maintaining efficacy through 52 weeks of treatment.
